Molecular Staging Overview

  • Founded
  • 1998
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $35.2M
Latest Deal Amount

Molecular Staging General Information

Description

Developer of technologies for the detection and measurement of proteins and nucleic acids. The company provides technologies for proteomics, genomics, pharmacogenomics and diagnostics applications. The company develops Whole Genome Amplification (WGA) technology which is designed to eliminate limitations created by scarce quantities of DNA samples.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Acquirer
Primary Office
  • 300 George Street
  • New Haven, CT 06511
  • United States
+1 (203) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Molecular Staging Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 27-Sep-2004 $35.2M 000.00 000.00 Completed Generating Revenue
5. Grant 08-Oct-2001 00.00 000.00 Completed
4. Later Stage VC (Series D) 000.00 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 06-Nov-2000 0000 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 04-Feb-1999 $5.17M $18.7M 00000 Completed Product Development
1. Early Stage VC (Series A) 01-Jan-1998 $13.5M $13.5M 000.00 Completed Product Development
To view Molecular Staging’s complete valuation and funding history, request access »

Molecular Staging Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 0,000,000 00.000000 00 00.00 00.00 00.00 00.000
Series C2 000,000 00.000000 000 000 00 000 0.000
Series C1 000,000 00.000000 000 000 00 000 0.000
Series B 700,000 $0.010000 $7.38 $7.38 1x $7.38 3.4%
Series A 4,500,000 $0.010000 $0.24 $3 $3 1x $3 21.87%
To view Molecular Staging’s complete cap table history, request access »

Molecular Staging Patents

Molecular Staging Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040101510-A1 Anticancer agents; antiarthritic agents; antiproliferative agents; measurement protein, calibration cell proliferation Abandoned 26-Nov-2002 0000000000
AU-2003293023-A1 Chemokine parc suppresses specific cytokine production Abandoned 26-Nov-2002 0000000000
AU-2003293023-A8 Chemokine parc suppresses specific cytokine production Withdrawn 26-Nov-2002 0000000000
US-20030152932-A1 For point mutations in small quantities of proteins/peptides Granted 08-Feb-2002 0000000000 00
AU-2003205076-A1 Detection method using dissociated rolling circle amplification Abandoned 08-Feb-2002 G01N33/537

Molecular Staging Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CHL Medical Partners Venture Capital Minority 000 0000 000000 0
CIBC Capital Partners Investment Bank Minority 000 0000 000000 0
Cooper Hill Partners Hedge Fund Minority 000 0000 000000 0
Domain Associates Venture Capital Minority 000 0000 000000 0
Investor PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »